Evaluation of efficacy and safety of upfront weekly nanoparticle albumin-bound paclitaxel for HER2-negative breast cancer

Akira Matsui, Akihiko Tatibana, Noriyuki Suzuki, Masaru Hirata, Yoko Oishi, Youhei Hamaguchi, Yuya Murata, Aiko Nagayama, Yuko Iwata, Yasushi Okamoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Taxanes are among the key drugs for breast cancer treatment. This study aimed to evaluate the efficacy of upfront weekly nanoparticle albumin-bound paclitaxel (Nab-PTX; 100 mg/m2) for human epidermal growth factor 2 (HER2)-negative breast cancer. Patients and Methods: Patients with stage II to IV breast cancer received 12 cycles of weekly 100 mg/m2 Nab-PTX as first-line treatment. Preoperative chemotherapy with anthracyclines after Nab-PTX was recommended. Results: From 2012 to 2014, we enrolled 66 patients. The overall response rate after Nab-PTX was 59.1% [95% confidence interval(CI)=47.2% to 71.0%), 63.6% in those with hormone receptor-positive tumors, and 36.4% in those with triple-negative tumors. The pathological complete response rate at surgery was 15% (95% CI=6.1% to 24.4%). Toxicity analysis showed grade 2 peripheral neuropathy in 38 patients (57.6%), grade 2/3 leukocytopenia in 29 (43.9%) and grade 2/3 liver dysfunction in five (7.5%). Conclusion: Weekly neoadjuvant Nab-PTX at 100 mg/m2 led to good response rates (59.1%) and was well tolerated.

Original languageEnglish
Pages (from-to)6481-6488
Number of pages8
JournalAnticancer research
Volume37
Issue number11
DOIs
Publication statusPublished - 2017 Nov 1
Externally publishedYes

Fingerprint

Epidermal Growth Factor
Nanoparticles
Breast Neoplasms
Safety
Confidence Intervals
Taxoids
Anthracyclines
Leukopenia
Peripheral Nervous System Diseases
Liver Diseases
Neoplasms
Hormones
Drug Therapy
Albumin-Bound Paclitaxel
Therapeutics
Pharmaceutical Preparations

Keywords

  • Breast cancer
  • HER2-negative
  • Nanoparticle albumin-bound paclitaxel
  • Pathological complete response
  • Response rate
  • Upfront chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Matsui, A., Tatibana, A., Suzuki, N., Hirata, M., Oishi, Y., Hamaguchi, Y., ... Okamoto, Y. (2017). Evaluation of efficacy and safety of upfront weekly nanoparticle albumin-bound paclitaxel for HER2-negative breast cancer. Anticancer research, 37(11), 6481-6488. https://doi.org/10.21873/anticanres.12104

Evaluation of efficacy and safety of upfront weekly nanoparticle albumin-bound paclitaxel for HER2-negative breast cancer. / Matsui, Akira; Tatibana, Akihiko; Suzuki, Noriyuki; Hirata, Masaru; Oishi, Yoko; Hamaguchi, Youhei; Murata, Yuya; Nagayama, Aiko; Iwata, Yuko; Okamoto, Yasushi.

In: Anticancer research, Vol. 37, No. 11, 01.11.2017, p. 6481-6488.

Research output: Contribution to journalArticle

Matsui, A, Tatibana, A, Suzuki, N, Hirata, M, Oishi, Y, Hamaguchi, Y, Murata, Y, Nagayama, A, Iwata, Y & Okamoto, Y 2017, 'Evaluation of efficacy and safety of upfront weekly nanoparticle albumin-bound paclitaxel for HER2-negative breast cancer', Anticancer research, vol. 37, no. 11, pp. 6481-6488. https://doi.org/10.21873/anticanres.12104
Matsui, Akira ; Tatibana, Akihiko ; Suzuki, Noriyuki ; Hirata, Masaru ; Oishi, Yoko ; Hamaguchi, Youhei ; Murata, Yuya ; Nagayama, Aiko ; Iwata, Yuko ; Okamoto, Yasushi. / Evaluation of efficacy and safety of upfront weekly nanoparticle albumin-bound paclitaxel for HER2-negative breast cancer. In: Anticancer research. 2017 ; Vol. 37, No. 11. pp. 6481-6488.
@article{efdf21b2c8d14d6a9a0888e30d740dcf,
title = "Evaluation of efficacy and safety of upfront weekly nanoparticle albumin-bound paclitaxel for HER2-negative breast cancer",
abstract = "Background: Taxanes are among the key drugs for breast cancer treatment. This study aimed to evaluate the efficacy of upfront weekly nanoparticle albumin-bound paclitaxel (Nab-PTX; 100 mg/m2) for human epidermal growth factor 2 (HER2)-negative breast cancer. Patients and Methods: Patients with stage II to IV breast cancer received 12 cycles of weekly 100 mg/m2 Nab-PTX as first-line treatment. Preoperative chemotherapy with anthracyclines after Nab-PTX was recommended. Results: From 2012 to 2014, we enrolled 66 patients. The overall response rate after Nab-PTX was 59.1{\%} [95{\%} confidence interval(CI)=47.2{\%} to 71.0{\%}), 63.6{\%} in those with hormone receptor-positive tumors, and 36.4{\%} in those with triple-negative tumors. The pathological complete response rate at surgery was 15{\%} (95{\%} CI=6.1{\%} to 24.4{\%}). Toxicity analysis showed grade 2 peripheral neuropathy in 38 patients (57.6{\%}), grade 2/3 leukocytopenia in 29 (43.9{\%}) and grade 2/3 liver dysfunction in five (7.5{\%}). Conclusion: Weekly neoadjuvant Nab-PTX at 100 mg/m2 led to good response rates (59.1{\%}) and was well tolerated.",
keywords = "Breast cancer, HER2-negative, Nanoparticle albumin-bound paclitaxel, Pathological complete response, Response rate, Upfront chemotherapy",
author = "Akira Matsui and Akihiko Tatibana and Noriyuki Suzuki and Masaru Hirata and Yoko Oishi and Youhei Hamaguchi and Yuya Murata and Aiko Nagayama and Yuko Iwata and Yasushi Okamoto",
year = "2017",
month = "11",
day = "1",
doi = "10.21873/anticanres.12104",
language = "English",
volume = "37",
pages = "6481--6488",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Evaluation of efficacy and safety of upfront weekly nanoparticle albumin-bound paclitaxel for HER2-negative breast cancer

AU - Matsui, Akira

AU - Tatibana, Akihiko

AU - Suzuki, Noriyuki

AU - Hirata, Masaru

AU - Oishi, Yoko

AU - Hamaguchi, Youhei

AU - Murata, Yuya

AU - Nagayama, Aiko

AU - Iwata, Yuko

AU - Okamoto, Yasushi

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background: Taxanes are among the key drugs for breast cancer treatment. This study aimed to evaluate the efficacy of upfront weekly nanoparticle albumin-bound paclitaxel (Nab-PTX; 100 mg/m2) for human epidermal growth factor 2 (HER2)-negative breast cancer. Patients and Methods: Patients with stage II to IV breast cancer received 12 cycles of weekly 100 mg/m2 Nab-PTX as first-line treatment. Preoperative chemotherapy with anthracyclines after Nab-PTX was recommended. Results: From 2012 to 2014, we enrolled 66 patients. The overall response rate after Nab-PTX was 59.1% [95% confidence interval(CI)=47.2% to 71.0%), 63.6% in those with hormone receptor-positive tumors, and 36.4% in those with triple-negative tumors. The pathological complete response rate at surgery was 15% (95% CI=6.1% to 24.4%). Toxicity analysis showed grade 2 peripheral neuropathy in 38 patients (57.6%), grade 2/3 leukocytopenia in 29 (43.9%) and grade 2/3 liver dysfunction in five (7.5%). Conclusion: Weekly neoadjuvant Nab-PTX at 100 mg/m2 led to good response rates (59.1%) and was well tolerated.

AB - Background: Taxanes are among the key drugs for breast cancer treatment. This study aimed to evaluate the efficacy of upfront weekly nanoparticle albumin-bound paclitaxel (Nab-PTX; 100 mg/m2) for human epidermal growth factor 2 (HER2)-negative breast cancer. Patients and Methods: Patients with stage II to IV breast cancer received 12 cycles of weekly 100 mg/m2 Nab-PTX as first-line treatment. Preoperative chemotherapy with anthracyclines after Nab-PTX was recommended. Results: From 2012 to 2014, we enrolled 66 patients. The overall response rate after Nab-PTX was 59.1% [95% confidence interval(CI)=47.2% to 71.0%), 63.6% in those with hormone receptor-positive tumors, and 36.4% in those with triple-negative tumors. The pathological complete response rate at surgery was 15% (95% CI=6.1% to 24.4%). Toxicity analysis showed grade 2 peripheral neuropathy in 38 patients (57.6%), grade 2/3 leukocytopenia in 29 (43.9%) and grade 2/3 liver dysfunction in five (7.5%). Conclusion: Weekly neoadjuvant Nab-PTX at 100 mg/m2 led to good response rates (59.1%) and was well tolerated.

KW - Breast cancer

KW - HER2-negative

KW - Nanoparticle albumin-bound paclitaxel

KW - Pathological complete response

KW - Response rate

KW - Upfront chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85032169840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032169840&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12104

DO - 10.21873/anticanres.12104

M3 - Article

C2 - 29061836

AN - SCOPUS:85032169840

VL - 37

SP - 6481

EP - 6488

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -